Clinical reference

Childhood and adolescent obesity

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources3 sources

Obesity in Pediatric Patients - StatPearls (NCBI Bookshelf NBK570626) - https://www.ncbi.nlm.nih.gov/books/NBK570626/ · Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-full.txt) · Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-clinical.txt)

Verified against3 documents

Obesity in Pediatric Patients - StatPearls (NCBI Bookshelf NBK570626) - https://www.ncbi.nlm.nih.gov/books/NBK570626/
Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-full.txt)
Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-clinical.txt)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (10)

A birth history of restricted growth in the womb, followed by fast catch-up size, or being oversized for gestational age
An extreme appetite with constant food-seeking behavior can point to an underlying genetic condition
A head injury just before the start of sudden weight gain hints at a hypothalamic cause [weight gain]
Bruising easily, weak muscles, tiredness, and fat concentrated around the trunk raise concern for Cushing syndrome [bruising · fatigue · muscle weakness]
Feeling cold, dry skin, and swelling at the front of the neck point toward an underactive thyroid [dry skin]
Frequent urination and excess thirst are markers of diabetes as a weight-related comorbidity [excess thirst · urinary frequency]
Headache together with changes in vision can signal pseudotumor cerebri [headache]
A limp with reduced ability to rotate the hip inward, plus hip or knee pain, suggests Blount disease or a slipped growth plate [groin pain · hip pain · joint pain · knee pain · limp]
Belly pain, vomiting, and yellowing of the skin point toward gallbladder disease or fatty liver disease [abdominal pain · jaundice · vomiting]
Irregular periods together with excess body hair and acne suggest polycystic ovary syndrome [abnormal uterine bleeding · acne · irregular periods]

Signs — what you find (9)

Slanted almond eyes, underdeveloped gonads, and unusually small hands and feet fit Prader-Willi syndrome
Low muscle tone, up-slanting eyes, a short neck, and creases across the palms fit Down syndrome
A rounded face with central fat and a fat pad between the shoulders points toward Cushing syndrome
Swelling of the optic disc, retinal degeneration, or involuntary eye movement on eye exam should prompt a specialist referral
Thickened, darkened skin at the back of the neck can signal insulin resistance or PCOS
Being unusually short for age is often tied to hormone deficiency or Albright hereditary osteodystrophy [short stature]
Tenderness over the belly or an enlarged liver on exam may point to fatty liver disease [hepatomegaly]
Reduced hip or knee movement on exam can signal a slipped growth plate or Blount disease
Blood pressure is checked with a properly fitted cuff as a routine part of the exam

Tests (10)

A fasting lipid panel, fasting glucose, and ALT are checked every two years once comorbidity screening begins
ALT is a more liver-specific marker of fat-related liver injury than AST
A raised fasting glucose is followed up with HbA1c or a post-load glucose reading from an oral glucose tolerance test
LH, FSH, and testosterone levels are drawn when PCOS is a possibility
Serum cortisol is the test used to work up possible Cushing syndrome
Hip and knee x-rays look for a slipped growth plate or Blount disease, and pelvic ultrasound looks for PCOS features
A brain CT or MRI can be used to look for a hypothalamic tumor
A sleep study confirms or rules out obstructive sleep apnea
Measuring spinal fluid opening pressure via lumbar puncture evaluates for pseudotumor cerebri
Routine lipid testing is skipped for ages 2 to 9 unless there is a positive family history

If not this — what else fits (7)

Slowed height growth points to an endocrine cause - low thyroid, a hypothalamic tumor, growth hormone deficiency, or Cushing syndrome
A significant prior head injury should raise concern for brain injury causing hypothalamic obesity
Excess hunger, unusual facial features, and developmental delay alongside obesity can point to a genetic syndrome such as Prader-Willi, confirmable by DNA methylation testing
Degeneration of the retina and involuntary eye movements point toward Bardet-Biedl or Alstrom syndrome
Developmental delay with severe obesity should raise concern for rare leptin or PCSK1 deficiency, checked with serum leptin, proinsulin, and insulin levels
MC4R gene deficiency causes obesity beginning very early in childhood, confirmed by genetic testing
Pseudotumor cerebri is a typical association of obesity, presenting with headaches and vision changes

SourceStatPearls "Obesity in Pediatric Patients" - disease-level clinical article

Presentation findings are traced to the source above.

FAMILY-BASED LIFESTYLE AND BEHAVIOUR CHANGE (NO DRUG THERAPY)

1st line

Dose source

Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-full.txt)

Why

The article makes this the treatment, not the preamble to one: behavioural change is what management of obesity in childhood rests on. It also closes off the tempting alternative - guidelines do not endorse waiting and watching.

Cautions

THE NUMBERS THAT DEFINE IT - from age 2 upwards, obesity means a BMI at or above the 95th percentile for the child's age and sex. The band immediately beneath it, from the 85th up to the 95th percentile, is overweight. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
THE CLASSES - class 1 is a BMI at or above the 95th percentile but under 120% of it; class 2 runs from 120% up to but not including 140% of that percentile; class 3 is 140% of the 95th percentile or more. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
HOW TO OPEN THE CONVERSATION - ask the family's permission before discussing weight or BMI at all. Do not label the child. Say that they are gaining too much weight for their age and height, rather than using the word obese. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
THE ADVICE, SPECIFIC ENOUGH TO FOLLOW - aim the plan at the whole family and make it concrete: stop sweetened drinks and fast food, put more fruit and vegetables on the plate, and build activity into the day. Telling a family to eat less and move more, with nothing more specific than that, is not enough. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
A RULE A FAMILY CAN REMEMBER - the 5-2-1-0 rule, short enough to say at the end of a consultation: 5 portions of fruit and vegetables a day, at most 2 hours of screens, 1 hour or more of active play, and 0 sugary drinks. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
SUGAR CEILING - the American Heart Association's limit for added sugar is 25 g a day, roughly 6 teaspoons, with sweetened drinks avoided entirely. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
ACTIVITY TARGET - between 6 and 17 years, aim for 60 minutes or more each day of activity brisk enough to raise the pulse. Between 3 and 5 years the target is not a block of time but movement spread across the whole day. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
SCREEN CEILING - the American Academy of Pediatrics caps screens at under 1 hour a day for ages 2 to 5, and at 2 hours a day once they are older. Below the age of 2, none at all, apart from video calls with family. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
NO SINGLE DIET WINS - no particular diet has been shown to beat the others for weight loss, so the approach that respects the family's own food is the one that will actually hold. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
TREAT THE HOUSEHOLD, NOT THE CHILD - getting the whole family active works better than aiming the advice at the child alone. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
THE INTENSITY THAT ACTUALLY WORKS IS HIGH - the behaviour-change programmes that shift weight run to as many as 22 sessions spread across 3 to 12 months and are delivered by a team. A single clinic conversation is the start of that, not the whole of it. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
WHAT MAY MAKE THE ADVICE IMPOSSIBLE - a family short of money may have little choice but to buy cheaper, more calorie-dense food, and in some districts it is not safe to send a child outdoors to play. Ask about both before prescribing an hour of outdoor play a day. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)

REFERRAL & SAFETY-NETTING (NO DRUG THERAPY)

1st line

Dose source

Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-clinical.txt)

Why

Carries the complications that are looked for rather than waited for, the tests the article schedules by age, and the causes that make a heavy child a referral rather than a diet.

Cautions

BLOOD TESTS BY AGE - from age 10, screen for lipid abnormalities, prediabetes, type 2 diabetes and liver dysfunction: fasting lipids, fasting glucose and ALT, repeated every 2 years. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
UNDER 10, TEST ON A REASON - between 2 and 9 years there is no routine lipid screen; do one if the family history points to it. In that age group, check glucose or liver function when something prompts it, such as acanthosis nigricans on the skin or diabetes in the family. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
THE GROWTH CHART IS THE DIAGNOSTIC TEST - what matters is the shape of the BMI curve over time, not a single reading. A slow climb through infancy, childhood or adolescence is a different thing from an abrupt jump, and an abrupt jump should prompt a look for stress at home or a medical cause - a tumour, an injury, an underactive thyroid, or a drug the child is taking. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
RED FLAG - A SHORT FAT CHILD IS AN ENDOCRINE REFERRAL, NOT A DIET: a child gaining weight while height growth slows or stalls needs an endocrine cause excluded - an underactive thyroid, a hypothalamic tumour, growth hormone deficiency, or Cushing syndrome. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
RED FLAG - GENETIC SYNDROME: constant hunger, unusual facial features, or delayed development alongside the obesity point towards a genetic cause. Delay in development together with very severe obesity should raise that suspicion on its own. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
RED FLAG - THE HIP AND THE KNEE: suspect a slipped upper femoral epiphysis in a child with hip pain and reduced internal rotation of the leg. Blount disease presents instead with pain at the knee, a limp, and marked bowing of the shins. Referred knee pain in a heavy adolescent is a slipped upper femoral epiphysis until an X-ray says otherwise. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
RED FLAG - HEADACHE AND VISION: idiopathic intracranial hypertension is uncommon but serious, and it appears most often in young women who are overweight or obese. It opens with headache and disturbed vision, and papilloedema may be visible on examination. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
ASK ABOUT SNORING - obstructive sleep apnoea in these children shows itself as snoring, a restless night, sleepiness by day, and behaviour that is out of character. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
ASK ABOUT SCHOOL AND MOOD - ask directly about anxiety, low mood, grades slipping, and bullying. Counselling may be needed to stop those symptoms taking root. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
WHEN TO ESCALATE - refer without delay for drug or surgical treatment once lifestyle and behavioural work has failed. The surgical threshold given is a BMI of 35 kg/m2 or more, or 120% of the 95th percentile on the age-and-sex chart, whichever figure is the lower, in adolescents whose skeletons are close to mature - and it is a specialist-centre decision. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
WHY IT MATTERS NOW RATHER THAN LATER - a child who stays obese usually becomes an adult who is obese, carrying the long-term health risks along with it, unless it is treated. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)

ORLISTAT

add-on - not a substitute

Strength120 mg

Formoral.solid

Adult dose and duration

120 mg orally, 3 times daily

Paediatric dose

(The licensed floor the article gives is 12 years: FDA approval covers children aged 12 and above who have obesity. The 120 mg three times daily it states is the same figure for adolescents as for adults. Neither a milligram-per-kilogram dose nor any dose for a child below 12 appears in the documents cited above, so none is printed.)

Dose by age
12 years and over:	120 mg three times daily (as for adults).

Dose source

Childhood and adolescent obesity - disease-level clinical article (childhood-obesity-full.txt)

Why

Indication and dose come from the same opened article, and it is the only weight-loss drug in that article with both. Indication: "Orlistat, approved by the FDA for use in children with obesity aged 12 years and older, is a pancreatic lipase inhibitor that promotes mild to moderate weight loss by inhibiting fat absorption." Dose: "The recommended dose is 120 mg orally, 3 times daily." It is placed second because the same article refuses it as a treatment on its own: "Evidence does not support weight loss medication use as a standalone therapy."

Cautions

NOT ON ITS OWN, AND NOT FIRST - a weight-loss drug is not a treatment by itself. It has a place only alongside intensive behavioural work that has already been tried and has not been enough. A prescription written instead of the behaviour work is the wrong prescription. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
AGE GATE - 12 YEARS. The article's approval statement covers children aged 12 and over, and it prints no dose for any younger age. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
WHAT THE FAMILY WILL ACTUALLY COMPLAIN ABOUT - the gut effects are what limit this drug in practice: wind, urgent stools, and oily stools. Warn about this before the first tablet or it will be stopped on day three. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
MOST OF WHAT IS SOLD FOR WEIGHT LOSS IS NOT FOR CHILDREN - many agents licensed for adults carry no FDA paediatric approval, and their safety and effectiveness in children are still under study. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
METFORMIN IS NOT A WEIGHT-LOSS DRUG HERE. Its FDA approval in children is for type 2 diabetes from age 10, not for weight. Children taking it for diabetes do shed a little to a moderate amount, but that is a by-product of treating the diabetes. A child with type 2 diabetes is treated for diabetes; obesity alone is not a metformin indication in this article. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
PHENTERMINE WITH TOPIRAMATE IS REFUSED BY THE ARTICLE ITSELF - it states the combination is not recommended in children. Topiramate does blunt appetite, but at the cost of slowed thinking, and it is teratogenic. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)
NO GLP-1 DOSE IS PRINTED HERE. The article names liraglutide as FDA-approved from age 12, but gives no strength, no frequency and no titration for it anywhere, so no dose claim can be taken from an opened document and none is invented. (Obesity in Pediatric Patients, StatPearls/NCBI Bookshelf, NBK570626)

Egyptian brands

Egyptian brand	Manufacturer	Indicative price
FATLOSE 120 MG 10 CAP.	EL-OBOUR > REPHARMA	20.00 EGP (2.00/unit)
CUT DOWN 120 MG 20 CAPS.	SABAA > NOVELL PHARMA	57.00 EGP (2.85/unit)
EASY SLIM 120MG 10 CAPS.	EUROPEAN EGYPTIAN PHARM. IND.	30.00 EGP (3.00/unit)
ORLISTYLE 120 MG 30 CAPS.	COPAD PHARMA	105.00 EGP (3.50/unit)
FINSHAPE 120MG 30 CAPS.	MASH PREMIERE	240.00 EGP (8.00/unit)
QUICK-SLIM 120 MG 30 CAPS.	MARCYRL PHARMACEUTICAL INDUSTRIES (MPI)	240.00 EGP (8.00/unit)
ORLISMART 120 MG 30 CAPS.	PHAROPHARMA	249.00 EGP (8.30/unit)
ORLISTAT 120 MG 30 CAPS.	SIGMA > OCTOBER PHARMA	249.00 EGP (8.30/unit)

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.